{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T03:27:35Z","timestamp":1778642855908,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,11,24]],"date-time":"2017-11-24T00:00:00Z","timestamp":1511481600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"The Research Foundation at the Norwegian Radium Hospital","award":["None"],"award-info":[{"award-number":["None"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s00428-017-2273-1","type":"journal-article","created":{"date-parts":[[2017,11,23]],"date-time":"2017-11-23T18:05:13Z","timestamp":1511460313000},"page":"425-432","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The diagnostic role of PTEN and ARID1A in serous effusions"],"prefix":"10.1007","volume":"472","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3332-8427","authenticated-orcid":false,"given":"Ben","family":"Davidson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Pinamonti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolors","family":"Cuevas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arild","family":"Holth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pio","family":"Zeppa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Hager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremias","family":"Wohlschlaeger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"T\u00f6tsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,11,24]]},"reference":[{"key":"2273_CR1","volume-title":"Serous effusions","year":"2011","unstructured":"Davidson B, Firat P, Michael CW (eds) (2011) Serous effusions. Springer, London, UK"},{"issue":"15","key":"2273_CR2","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1007\/s00018-017-2500-6","volume":"74","author":"P Malaney","year":"2017","unstructured":"Malaney P, Uversky VN, Dav\u00e9 V (2017) PTEN proteoforms in biology and disease. Cell Mol Life Sci 74(15):2783\u20132794. \nhttps:\/\/doi.org\/10.1007\/s00018-017-2500-6","journal-title":"Cell Mol Life Sci"},{"key":"2273_CR3","doi-asserted-by":"publisher","unstructured":"Hodges C, Kirkland JG, Crabtree GR (2016) The many roles of BAF (mSWI\/SNF) and PBAF complexes in cancer. Cold Spring Harb Perspect Med 6(8). \nhttps:\/\/doi.org\/10.1101\/cshperspect.a026930","DOI":"10.1101\/cshperspect.a026930"},{"issue":"2","key":"2273_CR4","doi-asserted-by":"publisher","first-page":"607","DOI":"10.3892\/or.2015.4421","volume":"35","author":"T Takeda","year":"2016","unstructured":"Takeda T, Banno K, Okawa R et al (2016) ARID1A gene mutation in ovarian and endometrial cancers (review). Oncol Rep 35(2):607\u2013613. \nhttps:\/\/doi.org\/10.3892\/or.2015.4421","journal-title":"Oncol Rep"},{"issue":"11","key":"2273_CR5","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1517\/14728222.2015.1062879","volume":"19","author":"BG Bitler","year":"2015","unstructured":"Bitler BG, Fatkhutdinov N, Zhang R (2015) Potential therapeutic targets in ARID1A-mutated cancers. Expert Opin Ther Targets 19(11):1419\u20131422. \nhttps:\/\/doi.org\/10.1517\/14728222.2015.1062879","journal-title":"Expert Opin Ther Targets"},{"issue":"9","key":"2273_CR6","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.2217\/fon.15.45","volume":"11","author":"I Gounaris","year":"2015","unstructured":"Gounaris I, Brenton JD (2015) Molecular pathogenesis of ovarian clear cell carcinoma. Future Oncol 11(9):1389\u20131405. \nhttps:\/\/doi.org\/10.2217\/fon.15.45","journal-title":"Future Oncol"},{"issue":"3","key":"2273_CR7","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.humpath.2013.10.018","volume":"45","author":"O Maiques","year":"2014","unstructured":"Maiques O, Santacana M, Valls J, Pallares J, Mirantes C, Gatius S, da Garc\u00eda D, Amant F, Pedersen HC, Dolcet X, Matias-Guiu X (2014) Optimal protocol for PTEN immunostaining; role of analytical and preanalytical variables in PTEN staining in normal and neoplastic endometrial, breast, and prostatic tissues. Hum Pathol 45(3):522\u2013532. \nhttps:\/\/doi.org\/10.1016\/j.humpath.2013.10.018","journal-title":"Hum Pathol"},{"issue":"5","key":"2273_CR8","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/modpathol.2011.208","volume":"25","author":"B Djordjevic","year":"2012","unstructured":"Djordjevic B, Hennessy BT, Li J, Barkoh BA, Luthra R, Mills GB, Broaddus RR (2012) Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing. Mod Pathol 25(5):699\u2013708. \nhttps:\/\/doi.org\/10.1038\/modpathol.2011.208","journal-title":"Mod Pathol"},{"issue":"1","key":"2273_CR9","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/PGP.0b013e3182230d00","volume":"31","author":"K Garg","year":"2012","unstructured":"Garg K, Broaddus RR, Soslow RA, Urbauer DL, Levine DA, Djordjevic B (2012) Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducible. Int J Gynecol Pathol 31(1):48\u201356. \nhttps:\/\/doi.org\/10.1097\/PGP.0b013e3182230d00","journal-title":"Int J Gynecol Pathol"},{"issue":"7","key":"2273_CR10","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1111\/his.12349","volume":"64","author":"M K\u00f6bel","year":"2014","unstructured":"K\u00f6bel M, Bak J, Bertelsen BI, Carpen O, Grove A, Hansen ES, Levin Jakobsen AM, Lidang M, M\u00e5sb\u00e4ck A, Tolf A, Gilks CB, Carlson JW (2014) Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry. Histopathology 64(7):1004\u20131013. \nhttps:\/\/doi.org\/10.1111\/his.12349","journal-title":"Histopathology"},{"issue":"10","key":"2273_CR11","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1158\/1055-9965.EPI-13-0391","volume":"22","author":"M K\u00f6bel","year":"2013","unstructured":"K\u00f6bel M, Kalloger SE, Lee S, Ovarian Tumor Tissue Analysis consortium et al (2013) Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium. Cancer Epidemiol Biomark Prev 22(10):1677\u20131686. \nhttps:\/\/doi.org\/10.1158\/1055-9965.EPI-13-0391","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"8","key":"2273_CR12","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1038\/modpathol.2013.34","volume":"26","author":"NG Ord\u00f3\u00f1ez","year":"2013","unstructured":"Ord\u00f3\u00f1ez NG (2013) Value of PAX8, PAX2, napsin A, carbonic anhydrase IX, and claudin-4 immunostaining in distinguishing pleural epithelioid mesothelioma from metastatic renal cell carcinoma. Mod Pathol 26(8):1132\u20131143. \nhttps:\/\/doi.org\/10.1038\/modpathol.2013.34","journal-title":"Mod Pathol"},{"issue":"4","key":"2273_CR13","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/modpathol.2012.200","volume":"26","author":"NG Ord\u00f3\u00f1ez","year":"2013","unstructured":"Ord\u00f3\u00f1ez NG (2013) Value of PAX8, PAX2, claudin-4, and h-caldesmon immunostaining in distinguishing peritoneal epithelioid mesotheliomas from serous carcinomas. Mod Pathol 26(4):553\u2013562. \nhttps:\/\/doi.org\/10.1038\/modpathol.2012.200","journal-title":"Mod Pathol"},{"issue":"5","key":"2273_CR14","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1097\/PAS.0b013e3181da7687","volume":"34","author":"AR Laury","year":"2010","unstructured":"Laury AR, Hornick JL, Perets R, Krane JF, Corson J, Drapkin R, Hirsch MS (2010) PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am J Surg Pathol 34(5):627\u2013635. \nhttps:\/\/doi.org\/10.1097\/PAS.0b013e3181da7687","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"2273_CR15","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/jclinpath-2015-203211","volume":"69","author":"T Kawai","year":"2016","unstructured":"Kawai T, Tominaga S, Hiroi S, Ogata S, Nakanishi K, Kawahara K, Sonobe H, Hiroshima K (2016) Peritoneal malignant mesothelioma (PMM), and primary peritoneal serous carcinoma (PPSC) and reactive mesothelial hyperplasia (RMH) of the peritoneum. Immunohistochemical and fluorescence in situ hybridisation (FISH) analyses. J Clin Pathol 69(8):706\u2013712. \nhttps:\/\/doi.org\/10.1136\/jclinpath-2015-203211","journal-title":"J Clin Pathol"},{"issue":"3","key":"2273_CR16","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/PAI.0b013e3182366531","volume":"20","author":"FF Gao","year":"2012","unstructured":"Gao FF, Krasinskas AM, Chivukula M (2012) Is PAX2 a reliable marker in differentiating diffuse malignant mesotheliomas of peritoneum from serous carcinomas of m\u00fcllerian origin? Appl Immunohistochem Mol Morphol 20(3):272\u2013276. \nhttps:\/\/doi.org\/10.1097\/PAI.0b013e3182366531","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"4","key":"2273_CR17","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/cncy.21392","volume":"122","author":"VY Jo","year":"2014","unstructured":"Jo VY, Cibas ES, Pinkus GS (2014) Claudin-4 immunohistochemistry is highly effective in distinguishing adenocarcinoma from malignant mesothelioma in effusion cytology. Cancer Cytopathol 122(4):299\u2013306. \nhttps:\/\/doi.org\/10.1002\/cncy.21392","journal-title":"Cancer Cytopathol"},{"key":"2273_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.humpath.2015.12.012","volume":"51","author":"J Andrici","year":"2016","unstructured":"Andrici J, Jung J, Sheen A, D\u2019Urso L, Sioson L, Pickett J, Parkhill TR, Verdonk B, Wardell KL, Singh A, Clarkson A, Watson N, Toon CW, Gill AJ (2016) Loss of BAP1 expression is very rare in peritoneal and gynecologic serous adenocarcinomas and can be useful in the differential diagnosis with abdominal mesothelioma. Hum Pathol 51:9\u201315. \nhttps:\/\/doi.org\/10.1016\/j.humpath.2015.12.012","journal-title":"Hum Pathol"},{"issue":"3","key":"2273_CR19","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00428-007-0448-x","volume":"451","author":"F Facchetti","year":"2007","unstructured":"Facchetti F, Lonardi S, Gentili F, Bercich L, Falchetti M, Tardanico R, Baronchelli C, Lucini L, Santin A, Murer B (2007) Claudin 4 identifies a wide spectrum of epithelial neoplasms and represents a very useful marker for carcinoma versus mesothelioma diagnosis in pleural and peritoneal biopsies and effusions. Virchows Arch 451(3):669\u2013680. \nhttps:\/\/doi.org\/10.1007\/s00428-007-0448-x","journal-title":"Virchows Arch"},{"issue":"6","key":"2273_CR20","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1309\/V025QRN3R9CJGNPX","volume":"127","author":"L Kleinberg","year":"2007","unstructured":"Kleinberg L, Holth A, Fridman E, Schwartz I, Shih IM, Davidson B (2007) The diagnostic role of claudins in serous effusions. Am J Clin Pathol 127(6):928\u2013937. \nhttps:\/\/doi.org\/10.1309\/V025QRN3R9CJGNPX","journal-title":"Am J Clin Pathol"},{"issue":"12","key":"2273_CR21","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/dc.20771","volume":"35","author":"B Davidson","year":"2007","unstructured":"Davidson B, Baekelandt M, Shih IM (2007) MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells. Diagn Cytopathol 35(12):756\u2013760. \nhttps:\/\/doi.org\/10.1002\/dc.20771","journal-title":"Diagn Cytopathol"},{"issue":"1","key":"2273_CR22","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.humpath.2015.08.020","volume":"47","author":"B Davidson","year":"2016","unstructured":"Davidson B, Stavnes HT, Hellesylt E, Hager T, Zeppa P, Pinamonti M, Wohlschlaeger J (2016) MMP-7 is a highly specific negative marker for benign and malignant mesothelial cells in serous effusions. Hum Pathol 47(1):104\u2013108. \nhttps:\/\/doi.org\/10.1016\/j.humpath.2015.08.020","journal-title":"Hum Pathol"},{"key":"2273_CR23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.humpath.2016.08.005","volume":"58","author":"B Davidson","year":"2016","unstructured":"Davidson B (2016) CD24 is highly useful in differentiating high-grade serous carcinoma from benign and malignant mesothelial cells. Hum Pathol 58:123\u2013127. \nhttps:\/\/doi.org\/10.1016\/j.humpath.2016.08.005","journal-title":"Hum Pathol"},{"issue":"11","key":"2273_CR24","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1097\/PAS.0b013e3181b6bde3","volume":"33","author":"Y Yuan","year":"2009","unstructured":"Yuan Y, Nymoen DA, Tuft Stavnes H et al (2009) Tenascin-X is a novel diagnostic marker of malignant mesothelioma. Am J Surg Pathol 33(11):1673\u20131682. \nhttps:\/\/doi.org\/10.1097\/PAS.0b013e3181b6bde3","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"2273_CR25","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/cncy.21353","volume":"122","author":"B Davidson","year":"2014","unstructured":"Davidson B (2014) Hepatocyte nuclear factor-1\u03b2 is not a specific marker of clear cell carcinoma in serous effusions. Cancer Cytopathol 122(2):153\u2013158. \nhttps:\/\/doi.org\/10.1002\/cncy.21353","journal-title":"Cancer Cytopathol"},{"issue":"5","key":"2273_CR26","doi-asserted-by":"publisher","first-page":"e62483","DOI":"10.1371\/journal.pone.0062483","volume":"8","author":"C Balb\u00e1s-Mart\u00ednez","year":"2013","unstructured":"Balb\u00e1s-Mart\u00ednez C, Rodr\u00edguez-Pinilla M, Casanova A (2013) ARID1A alterations are associated with FGFR3-wild type, poor-prognosis, urothelial bladder tumors. PLoS One 8(5):e62483. \nhttps:\/\/doi.org\/10.1371\/journal.pone.0062483","journal-title":"PLoS One"},{"issue":"2","key":"2273_CR27","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1093\/annonc\/mdw552","volume":"28","author":"D Morel","year":"2017","unstructured":"Morel D, Almouzni G, Soria JC, Postel-Vinay S (2017) Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism. Ann Oncol 28(2):254\u2013269. \nhttps:\/\/doi.org\/10.1093\/annonc\/mdw552","journal-title":"Ann Oncol"},{"key":"2273_CR28","doi-asserted-by":"publisher","first-page":"13837","DOI":"10.1038\/ncomms13837","volume":"7","author":"CT Williamson","year":"2016","unstructured":"Williamson CT, Miller R, Pemberton HN, Jones SE, Campbell J, Konde A, Badham N, Rafiq R, Brough R, Gulati A, Ryan CJ, Francis J, Vermulen PB, Reynolds AR, Reaper PM, Pollard JR, Ashworth A, Lord CJ (2016) ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A. Nat Commun 7:13837. \nhttps:\/\/doi.org\/10.1038\/ncomms13837","journal-title":"Nat Commun"},{"issue":"35","key":"2273_CR29","doi-asserted-by":"publisher","first-page":"56933","DOI":"10.18632\/oncotarget.10921","volume":"7","author":"SY Kwan","year":"2016","unstructured":"Kwan SY, Cheng X, Tsang YT et al (2016) Loss of ARID1A expression leads to sensitivity to ROS-inducing agent elesclomol in gynecologic cancer cells. Oncotarget 7(35):56933\u201356943. \n10.18632\/oncotarget.10921","journal-title":"Oncotarget"},{"issue":"7","key":"2273_CR30","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1158\/1535-7163.MCT-15-0554","volume":"15","author":"RE Miller","year":"2016","unstructured":"Miller RE, Brough R, Bajrami I, Williamson CT, McDade S, Campbell J, Kigozi A, Rafiq R, Pemberton H, Natrajan R, Joel J, Astley H, Mahoney C, Moore JD, Torrance C, Gordan JD, Webber JT, Levin RS, Shokat KM, Bandyopadhyay S, Lord CJ, Ashworth A (2016) Synthetic lethal targeting of ARID1A-mutant ovarian clear cell tumors with dasatinib. Mol Cancer Ther 15(7):1472\u20131484. \nhttps:\/\/doi.org\/10.1158\/1535-7163.MCT-15-0554","journal-title":"Mol Cancer Ther"},{"issue":"21","key":"2273_CR31","doi-asserted-by":"publisher","first-page":"5238","DOI":"10.1158\/1078-0432.CCR-15-2996","volume":"22","author":"K Berns","year":"2016","unstructured":"Berns K, Sonnenblick A, Gennissen A, Brohee S, Hijmans EM, Evers B, Fumagalli D, Desmedt C, Loibl S, Denkert C, Neven P, Guo W, Zhang F, Knijnenburg TA, Bosse T, van der Heijden MS, Hindriksen S, Nijkamp W, Wessels LFA, Joensuu H, Mills GB, Beijersbergen RL, Sotiriou C, Bernards R (2016) Loss of ARID1A activates ANXA1, which serves as a predictive biomarker for trastuzumab resistance. Clin Cancer Res 22(21):5238\u20135248. \nhttps:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2996","journal-title":"Clin Cancer Res"},{"key":"2273_CR32","unstructured":"Voss MH, Molina AM, Chen YB et al (2017) Phase II trial and correlative genomic analysis of everolimus plus bevacizumab in advanced non-clear cell renal cell carcinoma. Clin Oncol 2016 Sep 6. Pii: JCO679084 [Epub ahead of print]"},{"issue":"9","key":"2273_CR33","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1002\/ijc.30848","volume":"141","author":"JK Cowell","year":"2017","unstructured":"Cowell JK, Qin H, Hu T, Wu Q, Bhole A, Ren M (2017) Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1-driven leukemia\/lymphomas. Int J Cancer 141(9):1822\u20131829. \nhttps:\/\/doi.org\/10.1002\/ijc.30848","journal-title":"Int J Cancer"},{"issue":"8","key":"2273_CR34","doi-asserted-by":"publisher","first-page":"5865","DOI":"10.1007\/s13277-015-3258-9","volume":"36","author":"DH Koo","year":"2015","unstructured":"Koo DH, Lee HJ, Ahn JH, Yoon DH, Kim SB, Gong G, Son BH, Ahn SH, Jung KH (2015) Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer. Tumour Biol 36(8):5865\u20135871. \nhttps:\/\/doi.org\/10.1007\/s13277-015-3258-9","journal-title":"Tumour Biol"},{"issue":"11","key":"2273_CR35","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1158\/1078-0432.CCR-15-0965","volume":"22","author":"S Loibl","year":"2016","unstructured":"Loibl S, Darb-Esfahani S, Huober J, Klimowicz A, Furlanetto J, Lederer B, Hartmann A, Eidtmann H, Pfitzner B, Fasching PA, Tiemann K, Jackisch C, Mehta K, von Minckwitz G, Untch M, Denkert C (2016) Integrated analysis of PTEN and p4EBP1 protein expression as predictors for pCR in HER2-positive breast cancer. Clin Cancer Res 22(11):2675\u20132683. \nhttps:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0965","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2273_CR36","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1007\/s10120-016-0627-z","volume":"20","author":"Y Deguchi","year":"2017","unstructured":"Deguchi Y, Okabe H, Oshima N, Hisamori S, Minamiguchi S, Muto M, Sakai Y (2017) PTEN loss is associated with a poor response to trastuzumab in HER2-overexpressing gastroesophageal adenocarcinoma. Gastric Cancer 20(3):416\u2013427. \nhttps:\/\/doi.org\/10.1007\/s10120-016-0627-z","journal-title":"Gastric Cancer"},{"issue":"2","key":"2273_CR37","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.immuni.2017.02.001","volume":"46","author":"S George","year":"2017","unstructured":"George S, Miao D, Demetri GD, Adeegbe D, Rodig SJ, Shukla S, Lipschitz M, Amin-Mansour A, Raut CP, Carter SL, Hammerman P, Freeman GJ, Wu CJ, Ott PA, Wong KK, van Allen EM (2017) Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine Leiomyosarcoma. Immunity 46(2):197\u2013204. \nhttps:\/\/doi.org\/10.1016\/j.immuni.2017.02.001","journal-title":"Immunity"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00428-017-2273-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-017-2273-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-017-2273-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,4,5]],"date-time":"2018-04-05T00:33:16Z","timestamp":1522888396000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00428-017-2273-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,24]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["2273"],"URL":"https:\/\/doi.org\/10.1007\/s00428-017-2273-1","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,24]]}}}